Nasdaq:ACLX
Arcellx, Inc.
A clinical-stage immuno-oncology company developing novel antibody therapies for cancer, currently navigating a period of significant revenue contraction and elevated burn rates.
Key Metrics
Investment Thesis
Bull Case
Investors might consider ACLX if they believe the company has successfully identified a breakthrough asset capable of reversing its revenue trajectory and validating its high-risk clinical pipeline. The existing cash and marketable securities provide a runway that could allow the company to reach key clinical milestones or secure strategic partnerships before dilution becomes excessive.
Bear Case
The stock is unattractive due to the dramatic decline in sales and widening losses, which signals potential business model failure or severe commercial setbacks. With operating cash flow at -$210.3 million and a retained earnings deficit exceeding $725 million, the company lacks the financial stability to survive prolonged periods without external funding.
About Arcellx, Inc.
Arcellx, Inc. (ACLX) is a biotechnology company developing therapeutic antibodies for cancer treatment, primarily targeting the United States market with a focus on immuno-oncology. The company's recent financials reflect a significant contraction in revenue from over $107 million in 2024 to $22.3 million in 2025, alongside escalating net losses driven by high research and development expenditures.
Analysis
Management Discussion
Management is facing critical challenges as the company's revenue collapsed from $107.9 million in 2024 to just $22.3 million in 2025, while net losses widened significantly to $228.9 million. Despite having a substantial cash and securities balance of over $80 million at year-end, the aggressive burn rate suggests that current funding sources may not be sustainable without immediate positive catalysts or additional capital infusion.
Industry Overview
The immuno-oncology sector is characterized by high R&D costs, long development cycles, and intense competition from established pharmaceutical giants and biotech startups. Success in this field often depends on achieving clinical trial success and obtaining regulatory approval, where a single failure can lead to significant value erosion for a company with limited revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $110.3M | $107.9M | $22.3M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $110.3M | $107.9M | $22.3M |
| Operating Expenses | $191.3M | $200.2M | $245.5M | $275.4M |
| Operating Income | $-191.3M | $-89.9M | $-137.6M | $-253.1M |
| R&D | $149.6M | $133.8M | $157.1M | $157.6M |
| G&A | $41.7M | $66.3M | $88.4M | $117.8M |
| Stock-Based Comp | $21.5M | $41.8M | $61.1M | $77.9M |
| D&A | $1.3M | $2.0M | $5.2M | $6.7M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $19.9M | $32.3M | $24.2M |
| Pre-Tax Income | $-191.3M | $-70.0M | $-105.3M | $-228.9M |
| Income Tax | $0 | $663.0K | $2.1M | $69.0K |
| Continuing Ops | $-191.3M | $-70.7M | $-107.3M | $-228.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-188.7M | $-70.7M | $-107.3M | $-228.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-188.7M | $-70.7M | $-107.3M | $-228.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $266.9M | $716.4M | $599.3M | $462.2M |
| Cash & Equivalents | $64.2M | $394.6M | $105.7M | $80.3M |
| Marketable Securities | $190.7M | $307.4M | $481.7M | $370.1M |
| Prepaid Expenses | $12.0M | $12.4M | $11.7M | $11.8M |
| Other Current Assets | $0 | $1.9M | $208.0K | $0 |
| Long-Term Assets | $47.0M | $108.8M | $112.0M | $141.8M |
| PP&E (Net) | $11.2M | $42.7M | $46.5M | $42.6M |
| Operating Leases | $28.7M | $27.1M | $23.8M | $23.8M |
| LT Securities | — | $27.2M | $38.3M | $69.7M |
| Other LT Assets | $7.1M | $11.8M | $3.5M | $5.6M |
| Total Assets | $313.8M | $825.1M | $711.3M | $604.0M |
| Current Liabilities | $56.7M | $118.2M | $125.4M | $104.2M |
| Accounts Payable | $9.1M | $2.6M | $2.1M | $5.6M |
| Current Leases | $2.9M | $7.5M | $7.3M | $7.6M |
| Deferred Revenue | — | $50.5M | $59.1M | $56.0M |
| Other Current Liab | $33.1M | $39.3M | $230.0K | $0 |
| Long-Term Liabilities | $52.2M | $221.5M | $131.1M | $97.4M |
| LT Operating Leases | $31.3M | $50.8M | $46.5M | $44.3M |
| Other LT Liab | $20.9M | $0 | $8.6M | $0 |
| Total Liabilities | $108.9M | $339.8M | $256.5M | $201.6M |
| Shareholders' Equity | $205.0M | $485.4M | $454.8M | $402.4M |
| Paid-In Capital | $523.9M | $874.3M | $950.7M | $1.13B |
| Retained Earnings | $-318.8M | $-389.5M | $-496.8M | $-725.8M |
| AOCI | $-221.0K | $547.0K | $848.0K | $843.0K |
| Total L&E | $313.8M | $825.1M | $711.3M | $604.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-188.7M | $-70.7M | $-107.3M | $-228.9M |
| Non-Cash Adjustments | $79.2M | $44.5M | $63.3M | $74.0M |
| Working Capital Changes | $10.1M | $233.8M | $-39.4M | $-55.3M |
| Cash from Operations | $-99.3M | $207.6M | $-83.5M | $-210.3M |
| Capital Expenditures | $2.3M | $21.4M | $13.4M | $2.3M |
| Cash from Investing | $-117.7M | $-154.5M | $-183.0M | $86.3M |
| Cash from Financing | $252.6M | $279.2M | $-24.1M | $98.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.6M | $332.2M | $-290.6M | $-25.4M |
| Beginning Cash | $31.0M | $66.7M | $398.9M | $108.3M |
| Ending Cash | $66.7M | $398.9M | $108.3M | $82.9M |
Frequently Asked Questions
How does Arcellx, Inc. make money?
The company operates primarily through its drug discovery and development pipeline focused on oncology, with revenue derived from commercial sales or licensing agreements associated with its therapeutic candidates. Given the lack of diversified revenue streams in the provided data, operations are concentrated on advancing specific clinical assets toward potential regulatory approval and market launch.
What are the main risks for ACLX?
Severe revenue contraction over the last two years indicates potential commercialization failures or pipeline delays that threaten long-term viability. The company is burning through cash at an accelerating rate, with operating cash flow turning negative and relying heavily on capital raises to fund operations. Escalating R&D expenses combined with a lack of current profitability create substantial financial pressure in a competitive oncology landscape.
What is ACLX's competitive advantage?
The company possesses a proprietary portfolio of novel antibody technologies designed to target specific cancer mechanisms, potentially offering differentiated efficacy profiles compared to existing therapies. Its strategic focus on immuno-oncology places it in a high-growth sector with significant unmet medical needs, providing a strong rationale for future clinical value.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.